Nierenbeteiligung bei Kollagenosen

Abstract

Renal involvement is common and heterogenous in connective tissue diseases and has a main influence on prognosis and mortality. In systemic lupus erythematosus proliferative glomerulonephritis is the most common manifestation, while in primary Sjogren’s syndrome interstitial nephritis with tubular dysfunction is the predominant pathological feature. In systemic sclerosis the most serious renal manifestation is scleroderma renal crisis characterized by abrupt onset of hypertension and acute kidney injury associated with an increase in plasma renin activity. Risk factors for scleroderma renal crisis are diffuse cutaneous involvement, treatment with corticosteroids > 15 mg prednisolone/day and treatment with calcineurin inhibitors.

Regular measurement of urine sediment, proteinuria-to-urine creatinine ratio, tubular proteinuria, measurement of plasma creatinine, and office as well as home blood pressure monitoring are strongly recommended. Diagnostic kidney biopsy is essential in differentiating the different types of lupus nephritis and renal involvement in sjogren’s syndrome.

The optimal treatment of lupus nephritis varies with the classification of the morphological findings present on renal biopsy. The treatment of interstitial nephritis in sjogren’s syndrome consists of immunosuppression e. g. corticosteroids. Renal tubular acidosis should be corrected by sodium alkali and potassium alkali. Angiotensin-converting enzyme inhibitors play a major role in the treatment of scleroderma renal crisis, they should be continued also in patients progressing to end-stage renal disease.

Bei Kollagenosen sind häufig die Nieren mitbeteiligt – mit ungünstigem Einfluss auf die Prognose, insbesondere bei progredienter Niereninsuffizienz. Eine Nierenbiopsie ist wegen der Heterogenität der Nierenbeteiligung und der unterschiedlichen Therapieverfahren unabdingbar. Der folgende Beitrag gibt einen Überblick über die Formen und die Diagnostik der Nierenbeteiligung bei Kollagenosen und zeigt aktuelle Therapieempfehlungen.

Schlüsselwörter

Nierenbeteiligung - Kollagenosen - Lupusnephritis - interstitielle Nephritis - skleroderme renale Krise

Key words

renal involvement - connective tissue diseases - lupus nephritis - interstitial nephritis - scleroderma renal crisis

• Literatur

• 1 Petri M, Orbai AM, Alarcón GS. et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677-2686
• 2 Weening JJ, D’Agati VD, Schwartz MM. et al. International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-530
• 3 Chen S, Tang Z, Zhang Y. et al. Significance of histological crescent formation in patients with diffuse proliferative lupus nephritis. Am J Nephrol 2013; 38: 445-452
• 4 Bienaimé F, Legendre C, Terzi F. et al. Antiphospholipid syndrome and kidney disease. Kidney Int 2017; 91: 34-44
• 5 Dall’Era M, Cisternas MG, Smilek DE. et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol 2015; 67: 1305-1313
• 6 Bertsias GK, Tektonidou M, Amoura Z. et al. European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-1782
• 7 KDIGO. KDIGO guidelines, Chapter 12: Lupus nephritis. Kidney Int 2012; 2: 221-232
• 8 Houssiau FA, Vasconcelos C, D’Cruz D. et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69: 61-64
• 9 Tamirou F, Husson SN, Gruson D. et al. Brief report: The Euro-Lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti-Müllerian hormone. Arthritis Rheumatol 2017; 69: 1267-1271
• 10 Daleboudt GM, Reinders ME, den HartighJ. et al. Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil. Lupus 2013; 22: 171-179
• 11 Liu Z, Zhang H, Liu Z. et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 2015; 162: 18-26
• 12 Rovin BH, Furie R, Latinis K. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215-1226
• 13 Dooley MA, Jayne D, Ginzler EM. et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365: 1886-1895
• 14 Tamirou F, D’Cruz D, Sangle S. et al. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis 2016; 75: 526-531
• 15 Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum 2013; 65: 2154-2160
• 16 Shiboski CH, Shiboski SC, Seror R. et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 2017; 76: 9-16
• 17 Jasiek M, Karras A, Le GuernV. et al. A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren’s syndrome. Rheumatology (Oxford) 2017; 56: 362-370
• 18 Evans R, Zdebik A, Ciurtin C. et al. Renal involvement in primary Sjögren’s syndrome. Rheumatology (Oxford) 2015; 54: 1541-1548
• 19 Goules AV, Tatouli IP, Moutsopoulos HM. et al. Clinically significant renal involvement in primary Sjögren’s syndrome: clinical presentation and outcome. Arthritis Rheum 2013; 65: 2945-2953
• 20 Masaki Y, Sugai S, Umehara H. IgG4-related diseases including Mikulicz’s disease and sclerosing pancreatitis: diagnostic insights. J Rheumatol 2010; 37: 1380-1385
• 21 Gheitasi H, Kostov B, Solans R. et al. How are we treating our systemic patients with primary Sjögren syndrome?. Analysis of 1120 patients. Int Immunopharmacol 2015; 27: 194-199
• 22 Terrier B, Krastinova E, Marie I. et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood 2012; 119: 5996-6004
• 23 van den Hoogen F, Khanna D, Fransen J. et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-2747
• 24 Shanmugam VK, Steen VD. Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management. Curr Opin Rheumatol 2012; 24: 669-676
• 25 Shanmugam VK, Steen VD. Renal manifestations in scleroderma: evidence for subclinical renal disease as a marker of vasculopathy. Int J Rheumatol 2010; 2010: pii: 538589
• 26 Hudson M, Baron M, Tatibouet S. et al. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum 2014; 43: 666-672
• 27 Nguyen B, Assassi S, Arnett FC. et al. Association of RNA polymerase III antibodies with scleroderma renal crisis. J Rheumatol 2010; 37: 1068
• 28 Penn H, Howie AJ, Kingdon EJ. et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007; 100: 485-494
• 29 Montanelli G, Beretta L, Santaniello A. et al. Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series. Clin Exp Rheumatol 2013; 31: 135-139
• 30 Lynch BM, Stern EP, Ong V. et al. UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis. Clin Exp Rheumatol 2016; 34 (100) 106-109
• 31 Cozzi F, Marson P, Cardarelli S. et al. Prognosis of scleroderma renal crisis: a long-term observational study. Nephrol Dial Transplant 2012; 27: 4398-4403
• 32 Penn H, Quillinan N, Khan K. et al. Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. QJM 2013; 106: 839-848
• 33 Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000; 133: 600-603
• 34 Siva B, McDonald SP, Hawley CM. et al. End-stage kidney disease due to scleroderma--outcomes in 127 consecutive ANZDATA registry cases. Nephrol Dial Transplant 2011; 26: 3165-3171
• 35 Bertrand D, Dehay J, Ott J. et al. Kidney transplantation in patients with systemic sclerosis: a nationwide multicentre study. Transplant Int 2017; 30: 256-265
• 36 Kronbichler A, Mayer G. Renal involvement in autoimmune connective tissue diseases. BMC Med 2013; 11: 95